Top Markets
#1 QuantixAI QuantixAI +31.15%
#2 Prom Prom +29.37%
#3 MowCat MowCat +27.03%
#4 Tutorial Tutorial +25.45%
#5 Pons Pons +23.80%
#6 UnifAI Network UnifAI Network +23.49%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.80%
#8 Derive Derive +19.11%
#9 Versatize Coin Versatize Coin +16.66%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.19%
Coin of the day
QuantixAI QuantixAI
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Captor Therapeutics Spolka Akcyjna Captor Therapeutics Spolka Akcyjna

Captor Therapeutics Spolka Akcyjna

CTX
Rangering i aksjer #20516
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the... Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Aksjekurs
$20.27
Markedsverdi
$128.37M
Endring (1 dag)
-1.37%
Endring (1 år)
79.91%
Land
PL
Handel Captor Therapeutics Spolka Akcyjna (CTX)

Kategori

Healthcare
P/E-forhold for Captor Therapeutics Spolka Akcyjna (CTX)
P/E-forhold per 2026 TTM: 0
Ifølge Captor Therapeutics Spolka Akcyjna sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Captor Therapeutics Spolka Akcyjna fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.